Bibliothèque

Case report: Successful radical surgery following complete pathological remission of advanced HCC with Tislelizumab/Lenvatinib plus TACE.

The combination therapy of Tislelizumab plus Lenvatinib has recently emerged as the new standard of care for unresectable hepatocellular carcinoma (HCC). This treatment has demonstrated a significant …

Thérapies de Conversion

Xie, Y., Lyu, T., Zou, Y., & Wang, J. (2024). Case report: Successful radical surgery following complete pathological remission of advanced HCC with Tislelizumab/Lenvatinib plus TACE.. Front Oncol, 14, 1369567. https://doi.org/10.3389/fonc.2024.1369567

01/01/2024 Lire →

Surgical resection versus thermal ablation after intra-arterial conversion therapy for unresectable hepatocellular carcinoma: a multicenter retrospective one as per the STROBE guidelines.

PURPOSE: Intra-arterial conversion therapy (ICT) is a promising option for patients with unresectable hepatocellular carcinoma (uHCC). However, the selection of sequential therapeutic modalities is st…

Thérapies de Conversion

Du, Y., An, C., & Liu, W. (2024). Surgical resection versus thermal ablation after intra-arterial conversion therapy for unresectable hepatocellular carcinoma: a multicenter retrospective one as per the STROBE guidelines.. Int J Hyperthermia, 41(1), 2380001. https://doi.org/10.1080/02656736.2024.2380001

01/01/2024 Lire →

Comparison of immunochemotherapy and chemotherapy alone in conversion therapy for locally advanced unresectable esophageal squamous cell carcinoma.

BACKGROUND: The clinical value of preoperative immunochemotherapy and simple chemotherapy induction regimen in the conversion therapy of locally advanced unresectable esophageal squamous cell carcinom…

Thérapies de Conversion

Xu, Z., You, Z., Chen, M., Zhang, M., Shen, C., Xu, D., Xu, K., & Tian, W. (2024). Comparison of immunochemotherapy and chemotherapy alone in conversion therapy for locally advanced unresectable esophageal squamous cell carcinoma.. Front Oncol, 14, 1370353. https://doi.org/10.3389/fonc.2024.1370353

01/01/2024 Lire →

FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study.

PURPOSE: To explore the efficacy and safety of FOLFOXIRI plus cetuximab regimen as conversion therapy for patients with unresectable RAS/BRAF wild-type colorectal liver-limited metastases (CLM).PATIEN…

Thérapies de Conversion

Yang, W., Chen, D., Niu, Y., Wu, G., Huang, Z., Bi, X., Zhao, H., Che, X., & Sun, Y. (2024). FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study.. Front Oncol, 14, 1375906. https://doi.org/10.3389/fonc.2024.1375906

01/01/2024 Lire →

Resection of unresectable hepatocellular carcinoma after conversion therapy with apatinib and camrelizumab: a case report and literature review.

Hepatocellular carcinoma is a rather common malignant tumor. Most patients with hepatocellular carcinoma receive their diagnosis at an advanced stage, at which surgical resection is no longer appropri…

Thérapies de Conversion

Liu, X. L., Li, X. Z., Chu, Y. F., Liu, F., & Tian, H. (2024). Resection of unresectable hepatocellular carcinoma after conversion therapy with apatinib and camrelizumab: a case report and literature review.. Front Oncol, 14, 1280805. https://doi.org/10.3389/fonc.2024.1280805

01/01/2024 Lire →

"Ethical Care in Secret": Qualitative Data from an International Survey of Exploratory Therapists Working with Gender-Questioning Clients.

This is a mixed methods international survey of therapists ( = 89) belonging to Therapy First, an organization supporting the use of exploratory therapy, rather than gender affirmative therapy, with g…

Thérapies de Conversion

Jenkins, P., & Panozzo, D. (2024). "Ethical Care in Secret": Qualitative Data from an International Survey of Exploratory Therapists Working with Gender-Questioning Clients.. J Sex Marital Ther, 50(5), 557-582. https://doi.org/10.1080/0092623X.2024.2329761

01/01/2024 Lire →

Achieving complete remission in metastatic hepatocellular carcinoma with sintilimab plus sorafenib therapy followed by hepatic resection: a case report.

BACKGROUND: The synergistic effectiveness of combining immune checkpoint inhibitors with targeted therapies has shown promise in improving the conversion rate for unresectable hepatocellular carcinoma…

Thérapies de Conversion

Cui, K., Li, Z., Zhong, J., Shi, X., Zhao, L., Li, H., & Ma, Y. (2024). Achieving complete remission in metastatic hepatocellular carcinoma with sintilimab plus sorafenib therapy followed by hepatic resection: a case report.. Front Oncol, 14, 1355798. https://doi.org/10.3389/fonc.2024.1355798

01/01/2024 Lire →

Pathways to Care for Adolescents Attending a First Hormone Appointment at Canadian Gender Affirming Medical Clinics: A Cross-Sectional Analysis From the Trans Youth CAN! Study.

PURPOSE: Limited research has examined adolescents' pathways to gender-affirming medical care.METHODS: Enrollment in Trans Youth CAN! was at an initial appointment for hormone suppression or gender-af…

Thérapies de Conversion

Lawson, M. L., Gotovac, S., Couch, B., Gale, L., Vandermorris, A., Ghosh, S., & Bauer, G. R. (2024). Pathways to Care for Adolescents Attending a First Hormone Appointment at Canadian Gender Affirming Medical Clinics: A Cross-Sectional Analysis From the Trans Youth CAN! Study.. J Adolesc Health, 74(1), 140-147. https://doi.org/10.1016/j.jadohealth.2023.07.021

01/01/2024 Lire →

FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study.

BACKGROUND: Hepatic arterial infusion chemotherapy (HAIC) with the FOLFOX regimen has demonstrated efficacy in patients with unresectable hepatocellular carcinoma (HCC). The combined targeted and immu…

Thérapies de Conversion

Lu, Y. C., Yang, Y. C., Ma, D., Wang, J. Q., Hao, F. J., Chen, X. X., & Chen, Y. J. (2024). FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study.. Front Immunol, 15, 1471017. https://doi.org/10.3389/fimmu.2024.1471017

01/01/2024 Lire →

Analysis of the therapeutic effect and influencing factors on unresectable gastric cancer treated with conversion therapy.

BACKGROUND: Gastric cancer (GC) is one of the leading causes of cancer-related death in China, and with the extensive development of conversion therapy, the treatment of advanced unresectable gastric …

Thérapies de Conversion

Han, S., Han, S., Qian, J., Guo, M., & Fan, J. (2024). Analysis of the therapeutic effect and influencing factors on unresectable gastric cancer treated with conversion therapy.. Front Oncol, 14, 1435398. https://doi.org/10.3389/fonc.2024.1435398

01/01/2024 Lire →

Sarcomatoid carcinoma transformation in oral undifferentiated carcinoma following sequential immune combined targeted therapy: a case report.

The diagnosis and treatment of head and neck undifferentiated carcinoma (HNUC) present significant challenges. Herein, we present the case of a patient with advanced HNUC who underwent conversion surg…

Thérapies de Conversion

Li, J., Zhan, X., Shang, W., & Song, K. (2024). Sarcomatoid carcinoma transformation in oral undifferentiated carcinoma following sequential immune combined targeted therapy: a case report.. Front Immunol, 15, 1484915. https://doi.org/10.3389/fimmu.2024.1484915

01/01/2024 Lire →

Effects of switching from twice-daily tacrolimus to once-daily extended-release meltdose tacrolimus on cellular immune response.

BACKGROUND: LCP-Tacro [LCPT], a novel once-daily, extended-release formulation of tacrolimus, has a reduced C with comparable AUC exposure, requiring a ∼30% dose reduction in contrast to immediate-rel…

Thérapies de Conversion

Anft, M., Zgoura, P., Skrzypczyk, S., Dürr, M., Viebahn, R., Westhoff, T. H., Stervbo, U., & Babel, N. (2024). Effects of switching from twice-daily tacrolimus to once-daily extended-release meltdose tacrolimus on cellular immune response.. Front Transplant, 3, 1405070. https://doi.org/10.3389/frtra.2024.1405070

01/01/2024 Lire →